|
Título:
|
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
|
|
Autor/a:
|
Adams, S.; Schmid, P.; Rugo, H. S.; Winer, E. P.; Loirat, D.; Awada, A.; Cortés Castan, Javier
|
|
Otros autores:
|
[Adams S] Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA. [Schmid P] Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK. [Rugo HS] Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco. [Winer EP] Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. [Loirat D] Institut Curie, Paris, France; Oncology Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium. [Cortés J] Grup de Càncer de Mama i Melanoma, Vall d’Hebron Institut d’Oncologia (VHIO), Barcelona, Spain. Ramon y Cajal University Hospital, Madrid. IOB Institute of Oncology, Quiron Group, Barcelona, Spain; Departament de Salut |
|
Abstract:
|
Immunoterapia; Pembrolizumab; neoplàsies mamàries triple-negatives |
|
Abstract:
|
Inmunoterapia; Pembrolizumab; neoplasias mamarias triple-negativas |
|
Abstract:
|
Immunotherapy; Pembrolizumab; triple-negative breast neoplasms |
|
Abstract:
|
Background: Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. Patients and methods: Eligible patients had centrally confirmed mTNBC, ?1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1–positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ?24 weeks), progression-free survival, and overall survival. Results: All enrolled patients (N¼170) were women, 61.8% had PD-L1–positive tumors, and 43.5% had received ?3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7–9.9) in the total and 5.7% (2.4–12.2) in the PD-L1–positive populations. Disease control rate (95% CI) was 7.6% (4.4–12.7) and 9.5% (5.1–16.8), respectively. Median duration of response was not reached in the total (range, 1.2þ–21.5þ) and in the PD-L1–positive (range, 6.3–21.5þ) populations. Median PFS was 2.0 months (95% CI, 1.9–2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6–11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs. Conclusions: Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile. |
|
Abstract:
|
This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. |
|
Materia(s):
|
-Mama - Càncer
-Càncer - Immunoteràpia
-Immunotherapy
-DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
-TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
-ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos |
|
Derechos:
|
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
|
Tipo de documento:
|
Artículo
Artículo - Versión publicada |
|
Editor:
|
Elsevier
|
|
Compartir:
|
|
